STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 4/Lines 61-65	Abstract/Paragraph 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 5/Lines78-81	Abstract/Paragraph 4
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Pages 7-8/Lines 118-149	Introduction/Paragraphs 11-12
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 9/Lines 174-176	Introduction/Paragraph 15
Methods				
Study design	4	Present key elements of study design early in the paper	Page 10/Lines 178-181	Methods/Paragraph 16
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 10/Lines 182-187	Methods/Paragraph 16
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	Page 10/Lines 193-198	Methods/Paragraph 17
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	N/A	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 10/Lines 186-188	Methods/Paragraph 16
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Pages 11-13/Lines 200-246	Methods/Paragraphs 18-19
Bias	9	Describe any efforts to address potential sources of bias	Page 11/Lines 215-219	Methods/Paragraph 18
Study size	10	Explain how the study size was arrived at	Page 10/Lines 193-195	Methods/Paragraph 17
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 11/Lines 206-210	Methods/Paragraph 18

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 13/Lines 249-254	Methods/Paragraph 20
		(b) Describe any methods used to examine subgroups and interactions	N/A	N/A
		(c) Explain how missing data were addressed	Page 10/Lines 196-198	Methods/Paragraph 17
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	Page 10/Lines 196-198	Methods/Paragraph 17
		(e) Describe any sensitivity analyses	N/A	N/A
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 13/Lines 257-260	Results/Paragraph 21
		(b) Give reasons for non-participation at each stage	Page 13/Lines 257-258	Results/Paragraph 21
		(c) Consider use of a flow diagram	N/A	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 13/Lines 260-263	Results/Paragraph 21
		(b) Indicate number of participants with missing data for each variable of interest	Page 13/Lines 257-258	Results/Paragraph 21
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	Page 13/Lines 259-260	Results/Paragraph 21
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	Table 1, Table 2/Lines	Results/Paragraph 21
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A	N/A
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Pages 14-15/Lines 268-297	Results/Paragraphs 22-23
		(b) Report category boundaries when continuous variables were categorized	N/A	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Pages 15-16/Lines 299-311	Results/Paragraph 24
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 16/Lines 329-334	Discussion/Paragraph 26
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 21/Lines 426-437	Discussion/Paragraph 32

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Pages 17-18/Lines 342-344, 372-377	Discussion/Paragraphs 27, 29
Generalisability	21	Discuss the generalisability (external validity) of the study results	Pages 20-21/Lines 416-424	Discussion/Paragraph 31
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 22/Lines 455-462	Acknowledgments/Paragraph 35

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/jtd-23-1084
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.